PACB compared with BEAM: revenue, margins and what each company keeps, and the suppliers and customers both name

PACBPacific Biosciences of California, Inc.

Mkt capRevenueRevenue

BEAMBeam Therapeutics Inc.

Mkt capRevenueRevenue

Compare

PACBPacific Biosciences of California, Inc.

BEAMBeam Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PACB 2

—Illumina Cambridgeunlistedsupplier

—Buyerunlistedcustomer

Shared 0

No shared counterparties.

Only BEAM 9

LLYEli Lillycustomer

PFEPfizercustomer

SANASana Biotechnologycustomer

PRMEPrime Medicinesupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

5 more · BEAM chain ›

PACBPacific Biosciences of California, Inc.

2.62▼−9.81%· post 2.60

Mkt cap$809.7MRevenue$39MQ2 FY26Revenue$160MFY25

BEAMBeam Therapeutics Inc.

27.24▼−5.55%· post 27.04

ClosedOct 30 '26

Mkt cap$2.8BRevenue$490,000Q2 FY26Revenue$140MFY25

Compare

ClosedOct 30 '26

PACBPacific Biosciences of California, Inc.

BEAMBeam Therapeutics Inc.

2.62▼−9.81%post 2.60

Price

27.24▼−5.55%post 27.04

$809.7M

Mkt cap

$2.8B

Q2 FY26$39M

Revenue

$490,000Q2 FY26

FY25$160M

Revenue

$140MFY25

PACB2.62▼−9.81%vsBEAM27.24▼−5.55%ClosedOct 30 '26